Floatz logo

Burosumab

Rare Diseases

Bicetre Hospitalmonoclonal_antibodyPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Rare Diseases cohort.

Asset / SponsorPhaseRating
Irinotecan
Gradalis, Inc.
Phase 3B
Crofelemer
Napo Pharmaceuticals, Inc.
Phase 2/3B
FILGRASTIM
Hospices Civils de Lyon
Phase 2/3B
GEMOGENOVATUCEL-T
Gradalis, Inc.
Phase 3B
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Prisma Health-Upstate
Phase 2CCC

View all 11 →

Same molecule, other indications

Burosumab is also rated in:

X-linked dominant hypophosphatemic ricketsDormant
BB
Indicative ·
65 / 100
View asset →
hypophosphatemiaDormant
BB
Indicative ·
64 / 100
View asset →
hypophosphatemic ricketsDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →